Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.

Slides:

Advertisements

Similar presentations

Antoni Ribas, M.D., Ph.D. Professor of Medicine Professor of Surgery

Advertisements

The Journal of Immunology, 2013 March 27; 190: , IF=5.52

Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.

High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection Abstract.

October 23, 2014 John C. Lin, M.D. Ph.D. Vice President, Experimental Medicine Rational Combination of Immunotherapies in Preclinical Cancer Models.

The Promise of Immunotherapy for Cancer Treatment

Gianni L et al. Proc SABCS 2012;Abstract GS6-7.

Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.

Tumor immunotherapy 张沛张书铭张黎明赵宸赵世刚 Tumour Immunotherapy: questions Can immune stimulators combat cancer? Which forms of immunotherapy can be used?

Basic Immunology of the Mouse (and Human) Nicholas P. Restifo, MD October 19, 2015.

HOMING Ewing vs Paget Trapping vs homing (controlled arrest) “Seed and soil” Organ-specific metastatic colonization of favorable microenvironment.

Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.

Progress in Cancer Therapy Following Developments in Biopharma

Cancer immunotherapy: an update

Meredith Baker, MD PI: Bo Lu, MD – Radiation Oncology May 29th, 2014

Immuno and Epigenetic Therapies Xiaole Shirley Liu STAT115, STAT215, BIO298, BIST520.

The role of regulatory B cells on hepatocellular carcinoma progression Conclusion Results Fig2. (A and B) In vivo, Bregs in SCID mice increased the size.

Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology

Summary and Conclusion Hypothesis and Rationale

PD-L1 Expression in Metastatic Cutaneous Squamous Cell Carcinomas Nathaniel A. Slater, MD1, James Tidwell, MD2, George Sonnier, MD2, Paul Googe, MD1,3.

Fig. 1 GBM TIMs expand to inhibit vaccine-induced T-cell mediated tumor cytolysis via PD-1/PD-L1 regulatory pathway. (A, D) CD163, DAPI, (B, E) PD-L1,

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Tumor Immunity: Exploring the Role of a Checkpoint

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Table 1 Case # Age at primary Biopsy (year) Age at metastasis

Discussion Outline Cells of the Immune System.

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Figure 2 The association between CD8+ T‑cell density of the tumour

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Potential mechanisms of therapeutic synergy between epigenetic modulation and PD-1 pathway blockade. Potential mechanisms of therapeutic synergy between.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Targeting T Cell Co-receptors for Cancer Therapy

Nat. Rev. Endocrinol. doi: /nrendo

Translated by Krishna Karamsetty

Volume 26, Issue 2, Pages (February 2018)

Heather L Maecker, Zhong Yun, Holden T Maecker, Amato J Giaccia

Fig. 5 Local gel scaffold for T cell memory response.

Volume 24, Issue 1, Pages (January 2016)

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Volume 26, Issue 1, Pages (January 2018)

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented growth inhibition in WT mice. Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but not OVA Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but.

CD94/NKG2A expression and presence is higher on tumor-infiltrating immune cells. CD94/NKG2A expression and presence is higher on tumor-infiltrating immune.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

5FU-induced specific activation of CD8+ T cells.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate distinct mechanisms of regulation. PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Nanostring analysis of tumors after ILI and after combination limb infusion and ipilimumab. Nanostring analysis of tumors after ILI and after combination.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

Coincidence and prognostic significance of PD-1+ and CD103+ cells in HGSC. Serial sections from the 490-case TMA were stained with antibodies to CD103.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

Presentation transcript:

Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman

Overview T cell tolerance and immune inhibitory pathways in osteosarcoma Review our data

Immune tolerance in osteosarcoma Loss of Class I HLA expression in osteosarcoma tumors related to worse overall survival* CTLA4 polymorphisms are associated with higher risk of developing osteosarcoma** Metastatic osteosarcoma expresses T cell Ig/mucin molecule 3 (TIM3), which in other tumor settings inhibits the function of infiltrating CTL, leading to tumor progression # B7-H3 expression, a co-inhibitory protein involved in tumor immune escape from T cells, inversely correlates with CTL infiltration in human osteosarcoma, and is indicative of poor prognosis in osteosarcoma *Tshukahara et al., Cancer Sci 2006; **Liu et al, DNA Cell Bio 2011; #Shang et al., Oncol Lett Wang et al., Plos One 2013

Relative expression of PDL1 in osteosarcoma Shen J K et al. Cancer Immunol Res 2014;2: ©2014 by American Association for Cancer Research

Overall survival of 37 patients with osteosarcoma in relation to PDL1 gene expression. Shen J K et al. Cancer Immunol Res 2014;2: ©2014 by American Association for Cancer Research

Characterization of the origins of metastases. Shen J K et al. Cancer Immunol Res 2014;2: ©2014 by American Association for Cancer Research

Specific Aims Evaluate expression of PD-L1 on tumor cells and PD-1 on TILs in patient samples and metastatic osteosarcoma cell line (in vitro and in vivo) Evaluate the functional ability of TILs infiltrating metastatic tumors Evaluate the effect of PD-L1 blockade on development and progression of pulmonary metastases in vivo Evaluate the effect of combinational therapies (PD-L1 antibody + chemotherapy; PD-L1 antibody + ipilimumab)

PD-L1 is expressed in human metastatic osteosarcoma 50um Isotype Metastatic Osteosarcoma PD-L1 Primary Osteosarcoma 50um 12/ 16 (75% ) of metastatic tumors had some PD-L1 expression

PD-1 is expressed on human metastatic TILs 50um Isotype PD-1 50um Metastatic Osteosarcoma Primary Osteosarcoma -13/16 (81%) of metastatic tumors had PD-1+ TILs -In 11/16 (70%) metastatic tumors, PD-1 expression on TILs correlated with PD-L1 expression on tumor cells

PD-L1 expression is increased in K7M2 osteosarcoma cells PD-L1 % of Maximum Pre Implantation Post Tumor 30%

TILs from lung metastases are PD-1+ %PD1+ SPLEEN CD8TIL CD8 * CD8 PD-1 SPLEENTIL 94% 6% 87% 13% Isotype PD1 Healthy Lung Late Disease Lung Early Disease Lung 50 µm

TILs are functionally impaired in the presence of tumor cells * * %IFNγ+ * * * -+-+ Ag PD-L1+ K7M2 PD-L1- 4T1 %TNF+ * * * -+-+ Ag PD-L1+ K7M2 PD-L1- 4T1 %IL-2+ * * -+-+ Ag PD-L1+ K7M2 PD-L1- 4T1

%IFNγ+ Control PD-L1 Ab * * %TNF+ * * * Control PD-L1 Ab %IL-2+ * * * Control PD-L1 Ab A. B. C. PD-L1 blockade restores function to TILs

Blockade of PD-1:PD-L1 significantly enhances survival in metastatic osteosarcoma model Days post implant Percent Survival P=0.0005

30 day PD-L1 antibody treatment does not significantly improve survival compared to 15 day treatment Is immune escape occurring?

PD-L1 antibody treatment changes inhibitory receptor expression * *

PD-L1 antibody treated osteosarcoma is resistant to additional treatment when injected into naïve mice. PD-L1 % of Maximum *

Combinational PD-L1 antibody treatment coupled with conventional chemotherapy The combination improves survival as compared to chemotherapy alone but is similar to PD-L1 antibody alone.

Combinational PD-L1 antibody coupled with CTLA-4 antibody treatment improves survival

In conclusion PD-1/PD-L1 interaction induces immune tolerance in metastatic osteosarcoma PD-L1 blockade improves survival but not 100% Resistance to therapy develops by up-regulation of alternative immune escape pathways Combinational immune therapies may have the highest impact on disease control in metastatic osteosarcoma

Joseph Blattman Danielle Lussier John Johnson Lauren O’Neill Lizbeth Nieves Megan McAfee Susan Holechek Paul Dickman Patients and families Acknowledgements